nodes	percent_of_prediction	percent_of_DWPC	metapath
Adefovir Dipivoxil—ABCC5—Fluorouracil—urinary bladder cancer	0.212	0.348	CbGbCtD
Adefovir Dipivoxil—ABCC5—Cisplatin—urinary bladder cancer	0.18	0.295	CbGbCtD
Adefovir Dipivoxil—ABCC4—Fluorouracil—urinary bladder cancer	0.102	0.167	CbGbCtD
Adefovir Dipivoxil—ABCC4—Methotrexate—urinary bladder cancer	0.0563	0.0921	CbGbCtD
Adefovir Dipivoxil—SLC22A8—Methotrexate—urinary bladder cancer	0.0352	0.0576	CbGbCtD
Adefovir Dipivoxil—SLC22A6—Methotrexate—urinary bladder cancer	0.0245	0.0401	CbGbCtD
Adefovir Dipivoxil—AK2—prostate gland—urinary bladder cancer	0.00731	0.0666	CbGeAlD
Adefovir Dipivoxil—SLC22A8—urine—urinary bladder cancer	0.00588	0.0535	CbGeAlD
Adefovir Dipivoxil—NME1—prostate gland—urinary bladder cancer	0.00561	0.0511	CbGeAlD
Adefovir Dipivoxil—AK4—prostate gland—urinary bladder cancer	0.00541	0.0492	CbGeAlD
Adefovir Dipivoxil—NME2—prostate gland—urinary bladder cancer	0.00529	0.0481	CbGeAlD
Adefovir Dipivoxil—NME1-NME2—female reproductive system—urinary bladder cancer	0.00527	0.0479	CbGeAlD
Adefovir Dipivoxil—AK4—seminal vesicle—urinary bladder cancer	0.00458	0.0416	CbGeAlD
Adefovir Dipivoxil—NME2—epithelium—urinary bladder cancer	0.00389	0.0354	CbGeAlD
Adefovir Dipivoxil—NME1—renal system—urinary bladder cancer	0.00383	0.0348	CbGeAlD
Adefovir Dipivoxil—AK4—renal system—urinary bladder cancer	0.00369	0.0336	CbGeAlD
Adefovir Dipivoxil—AK4—urethra—urinary bladder cancer	0.00362	0.033	CbGeAlD
Adefovir Dipivoxil—AK2—vagina—urinary bladder cancer	0.00361	0.0329	CbGeAlD
Adefovir Dipivoxil—NME2—renal system—urinary bladder cancer	0.0036	0.0328	CbGeAlD
Adefovir Dipivoxil—NME1-NME2—lymph node—urinary bladder cancer	0.00308	0.028	CbGeAlD
Adefovir Dipivoxil—ABCC5—prostate gland—urinary bladder cancer	0.00307	0.0279	CbGeAlD
Adefovir Dipivoxil—NME1—female reproductive system—urinary bladder cancer	0.00306	0.0279	CbGeAlD
Adefovir Dipivoxil—AK4—female reproductive system—urinary bladder cancer	0.00295	0.0269	CbGeAlD
Adefovir Dipivoxil—NME2—female reproductive system—urinary bladder cancer	0.00289	0.0263	CbGeAlD
Adefovir Dipivoxil—AK4—vagina—urinary bladder cancer	0.00267	0.0243	CbGeAlD
Adefovir Dipivoxil—AK2—lymph node—urinary bladder cancer	0.00234	0.0213	CbGeAlD
Adefovir Dipivoxil—SLC22A3—prostate gland—urinary bladder cancer	0.0022	0.02	CbGeAlD
Adefovir Dipivoxil—ABCC4—prostate gland—urinary bladder cancer	0.00213	0.0194	CbGeAlD
Adefovir Dipivoxil—SLC22A8—prostate gland—urinary bladder cancer	0.00211	0.0192	CbGeAlD
Adefovir Dipivoxil—SLC22A3—seminal vesicle—urinary bladder cancer	0.00186	0.0169	CbGeAlD
Adefovir Dipivoxil—NME1—lymph node—urinary bladder cancer	0.00179	0.0163	CbGeAlD
Adefovir Dipivoxil—AK4—lymph node—urinary bladder cancer	0.00173	0.0157	CbGeAlD
Adefovir Dipivoxil—NME2—lymph node—urinary bladder cancer	0.00169	0.0154	CbGeAlD
Adefovir Dipivoxil—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.00155	0.0141	CbGeAlD
Adefovir Dipivoxil—ABCC5—vagina—urinary bladder cancer	0.00152	0.0138	CbGeAlD
Adefovir Dipivoxil—SLC22A3—renal system—urinary bladder cancer	0.0015	0.0136	CbGeAlD
Adefovir Dipivoxil—SLC22A3—urethra—urinary bladder cancer	0.00147	0.0134	CbGeAlD
Adefovir Dipivoxil—ABCC4—renal system—urinary bladder cancer	0.00145	0.0132	CbGeAlD
Adefovir Dipivoxil—SLC22A8—renal system—urinary bladder cancer	0.00144	0.0131	CbGeAlD
Adefovir Dipivoxil—SLC22A3—female reproductive system—urinary bladder cancer	0.0012	0.0109	CbGeAlD
Adefovir Dipivoxil—ABCC4—female reproductive system—urinary bladder cancer	0.00116	0.0106	CbGeAlD
Adefovir Dipivoxil—SLC22A3—vagina—urinary bladder cancer	0.00108	0.00986	CbGeAlD
Adefovir Dipivoxil—ABCC5—lymph node—urinary bladder cancer	0.000981	0.00892	CbGeAlD
Adefovir Dipivoxil—SLC22A3—lymph node—urinary bladder cancer	0.000701	0.00638	CbGeAlD
Adefovir Dipivoxil—ABCC4—lymph node—urinary bladder cancer	0.00068	0.00619	CbGeAlD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000645	0.00516	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000641	0.00512	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Validated targets of C-MYC transcriptional activation—CDK4—urinary bladder cancer	0.000637	0.00509	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000625	0.005	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.000615	0.00491	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000572	0.00457	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Validated targets of C-MYC transcriptional activation—CREBBP—urinary bladder cancer	0.000556	0.00444	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—GSTZ1—urinary bladder cancer	0.00055	0.0044	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Posttranslational regulation of adherens junction stability and dissassembly—SRC—urinary bladder cancer	0.000549	0.00438	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.000537	0.00429	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Validated targets of C-MYC transcriptional activation—MMP9—urinary bladder cancer	0.000527	0.00421	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—GSTO2—urinary bladder cancer	0.000521	0.00417	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—NAT1—urinary bladder cancer	0.000521	0.00417	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000516	0.00412	CbGpPWpGaD
Adefovir Dipivoxil—Pharyngitis—Gemcitabine—urinary bladder cancer	0.000511	0.00332	CcSEcCtD
Adefovir Dipivoxil—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000509	0.00331	CcSEcCtD
Adefovir Dipivoxil—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000506	0.00329	CcSEcCtD
Adefovir Dipivoxil—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.000506	0.00329	CcSEcCtD
Adefovir Dipivoxil—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000505	0.00328	CcSEcCtD
Adefovir Dipivoxil—Pharyngitis—Fluorouracil—urinary bladder cancer	0.000503	0.00327	CcSEcCtD
Adefovir Dipivoxil—NME2—Validated targets of C-MYC transcriptional activation—EP300—urinary bladder cancer	0.0005	0.00399	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000499	0.00398	CbGpPWpGaD
Adefovir Dipivoxil—Cough increased—Doxorubicin—urinary bladder cancer	0.000496	0.00323	CcSEcCtD
Adefovir Dipivoxil—Anaemia—Thiotepa—urinary bladder cancer	0.000493	0.0032	CcSEcCtD
Adefovir Dipivoxil—Hepatocellular injury—Epirubicin—urinary bladder cancer	0.000491	0.00319	CcSEcCtD
Adefovir Dipivoxil—Hyperkalaemia—Epirubicin—urinary bladder cancer	0.000483	0.00314	CcSEcCtD
Adefovir Dipivoxil—Renal failure—Etoposide—urinary bladder cancer	0.000482	0.00313	CcSEcCtD
Adefovir Dipivoxil—NME1—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—urinary bladder cancer	0.000481	0.00384	CbGpPWpGaD
Adefovir Dipivoxil—Jaundice—Etoposide—urinary bladder cancer	0.000478	0.0031	CcSEcCtD
Adefovir Dipivoxil—Creatinine increased—Doxorubicin—urinary bladder cancer	0.000477	0.0031	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—UGT2B7—urinary bladder cancer	0.000477	0.00381	CbGpPWpGaD
Adefovir Dipivoxil—Bone pain—Doxorubicin—urinary bladder cancer	0.000474	0.00308	CcSEcCtD
Adefovir Dipivoxil—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000474	0.00308	CcSEcCtD
Adefovir Dipivoxil—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000472	0.00307	CcSEcCtD
Adefovir Dipivoxil—Urethral disorder—Cisplatin—urinary bladder cancer	0.000471	0.00306	CcSEcCtD
Adefovir Dipivoxil—Cough—Thiotepa—urinary bladder cancer	0.000465	0.00302	CcSEcCtD
Adefovir Dipivoxil—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.000464	0.00301	CcSEcCtD
Adefovir Dipivoxil—Hepatocellular injury—Doxorubicin—urinary bladder cancer	0.000455	0.00295	CcSEcCtD
Adefovir Dipivoxil—Myalgia—Thiotepa—urinary bladder cancer	0.000454	0.00295	CcSEcCtD
Adefovir Dipivoxil—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000451	0.00293	CcSEcCtD
Adefovir Dipivoxil—SLC22A8—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000449	0.00359	CbGpPWpGaD
Adefovir Dipivoxil—Hyperkalaemia—Doxorubicin—urinary bladder cancer	0.000447	0.0029	CcSEcCtD
Adefovir Dipivoxil—NME2—Validated targets of C-MYC transcriptional activation—MYC—urinary bladder cancer	0.000435	0.00348	CbGpPWpGaD
Adefovir Dipivoxil—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000435	0.00282	CcSEcCtD
Adefovir Dipivoxil—Back pain—Gemcitabine—urinary bladder cancer	0.000434	0.00282	CcSEcCtD
Adefovir Dipivoxil—Urethral disorder—Etoposide—urinary bladder cancer	0.000431	0.0028	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—CYP4B1—urinary bladder cancer	0.000429	0.00343	CbGpPWpGaD
Adefovir Dipivoxil—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000427	0.00277	CcSEcCtD
Adefovir Dipivoxil—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000426	0.00277	CcSEcCtD
Adefovir Dipivoxil—Hepatic failure—Methotrexate—urinary bladder cancer	0.000424	0.00275	CcSEcCtD
Adefovir Dipivoxil—Skin disorder—Thiotepa—urinary bladder cancer	0.000423	0.00275	CcSEcCtD
Adefovir Dipivoxil—Malnutrition—Cisplatin—urinary bladder cancer	0.000418	0.00272	CcSEcCtD
Adefovir Dipivoxil—Anorexia—Thiotepa—urinary bladder cancer	0.000415	0.0027	CcSEcCtD
Adefovir Dipivoxil—Anaemia—Gemcitabine—urinary bladder cancer	0.000415	0.00269	CcSEcCtD
Adefovir Dipivoxil—Flatulence—Cisplatin—urinary bladder cancer	0.000412	0.00268	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000411	0.00328	CbGpPWpGaD
Adefovir Dipivoxil—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.000408	0.00265	CcSEcCtD
Adefovir Dipivoxil—Anaemia—Fluorouracil—urinary bladder cancer	0.000408	0.00265	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—SLC19A1—urinary bladder cancer	0.000406	0.00324	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000403	0.00322	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Validated targets of C-MYC transcriptional activation—MMP9—urinary bladder cancer	0.000399	0.00319	CbGpPWpGaD
Adefovir Dipivoxil—Hepatic failure—Epirubicin—urinary bladder cancer	0.000397	0.00258	CcSEcCtD
Adefovir Dipivoxil—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000397	0.00258	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—PRSS3—urinary bladder cancer	0.000395	0.00316	CbGpPWpGaD
Adefovir Dipivoxil—Cough—Gemcitabine—urinary bladder cancer	0.000391	0.00254	CcSEcCtD
Adefovir Dipivoxil—Anaemia—Cisplatin—urinary bladder cancer	0.000386	0.00251	CcSEcCtD
Adefovir Dipivoxil—NME1—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—urinary bladder cancer	0.000386	0.00309	CbGpPWpGaD
Adefovir Dipivoxil—Dyspepsia—Thiotepa—urinary bladder cancer	0.000383	0.00249	CcSEcCtD
Adefovir Dipivoxil—Chest pain—Gemcitabine—urinary bladder cancer	0.000382	0.00248	CcSEcCtD
Adefovir Dipivoxil—Myalgia—Gemcitabine—urinary bladder cancer	0.000382	0.00248	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—GSTZ1—urinary bladder cancer	0.000381	0.00305	CbGpPWpGaD
Adefovir Dipivoxil—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000379	0.00246	CcSEcCtD
Adefovir Dipivoxil—NME1—Validated targets of C-MYC transcriptional activation—EP300—urinary bladder cancer	0.000379	0.00303	CbGpPWpGaD
Adefovir Dipivoxil—Decreased appetite—Thiotepa—urinary bladder cancer	0.000378	0.00246	CcSEcCtD
Adefovir Dipivoxil—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000377	0.00245	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000376	0.00244	CcSEcCtD
Adefovir Dipivoxil—Chest pain—Fluorouracil—urinary bladder cancer	0.000376	0.00244	CcSEcCtD
Adefovir Dipivoxil—Myalgia—Fluorouracil—urinary bladder cancer	0.000376	0.00244	CcSEcCtD
Adefovir Dipivoxil—SLC22A6—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000375	0.003	CbGpPWpGaD
Adefovir Dipivoxil—Renal impairment—Epirubicin—urinary bladder cancer	0.000375	0.00243	CcSEcCtD
Adefovir Dipivoxil—Back pain—Etoposide—urinary bladder cancer	0.000371	0.00241	CcSEcCtD
Adefovir Dipivoxil—Hepatic failure—Doxorubicin—urinary bladder cancer	0.000367	0.00239	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—GSTO2—urinary bladder cancer	0.000361	0.00289	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—NAT1—urinary bladder cancer	0.000361	0.00289	CbGpPWpGaD
Adefovir Dipivoxil—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000359	0.00233	CcSEcCtD
Adefovir Dipivoxil—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000358	0.00233	CcSEcCtD
Adefovir Dipivoxil—NME2—Validated targets of C-MYC transcriptional activation—TP53—urinary bladder cancer	0.000358	0.00286	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000357	0.00286	CbGpPWpGaD
Adefovir Dipivoxil—Myalgia—Cisplatin—urinary bladder cancer	0.000356	0.00231	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000356	0.00231	CcSEcCtD
Adefovir Dipivoxil—Skin disorder—Gemcitabine—urinary bladder cancer	0.000356	0.00231	CcSEcCtD
Adefovir Dipivoxil—Anaemia—Etoposide—urinary bladder cancer	0.000354	0.0023	CcSEcCtD
Adefovir Dipivoxil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000354	0.0023	CcSEcCtD
Adefovir Dipivoxil—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000353	0.00229	CcSEcCtD
Adefovir Dipivoxil—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000352	0.00229	CcSEcCtD
Adefovir Dipivoxil—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000352	0.00229	CcSEcCtD
Adefovir Dipivoxil—Anorexia—Gemcitabine—urinary bladder cancer	0.000349	0.00227	CcSEcCtD
Adefovir Dipivoxil—ABCC5—NRF2 pathway—NQO1—urinary bladder cancer	0.000348	0.00278	CbGpPWpGaD
Adefovir Dipivoxil—Renal impairment—Doxorubicin—urinary bladder cancer	0.000347	0.00225	CcSEcCtD
Adefovir Dipivoxil—Abdominal pain—Thiotepa—urinary bladder cancer	0.000344	0.00224	CcSEcCtD
Adefovir Dipivoxil—Body temperature increased—Thiotepa—urinary bladder cancer	0.000344	0.00224	CcSEcCtD
Adefovir Dipivoxil—Anorexia—Fluorouracil—urinary bladder cancer	0.000343	0.00223	CcSEcCtD
Adefovir Dipivoxil—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000335	0.00217	CcSEcCtD
Adefovir Dipivoxil—Cough—Etoposide—urinary bladder cancer	0.000334	0.00217	CcSEcCtD
Adefovir Dipivoxil—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000334	0.00217	CcSEcCtD
Adefovir Dipivoxil—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000334	0.00217	CcSEcCtD
Adefovir Dipivoxil—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000334	0.00217	CcSEcCtD
Adefovir Dipivoxil—Skin disorder—Cisplatin—urinary bladder cancer	0.000331	0.00215	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—UGT2B7—urinary bladder cancer	0.000331	0.00264	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Validated targets of C-MYC transcriptional activation—MYC—urinary bladder cancer	0.00033	0.00264	CbGpPWpGaD
Adefovir Dipivoxil—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000329	0.00214	CcSEcCtD
Adefovir Dipivoxil—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000328	0.00213	CcSEcCtD
Adefovir Dipivoxil—Chest pain—Etoposide—urinary bladder cancer	0.000326	0.00212	CcSEcCtD
Adefovir Dipivoxil—Anorexia—Cisplatin—urinary bladder cancer	0.000325	0.00211	CcSEcCtD
Adefovir Dipivoxil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000324	0.0021	CcSEcCtD
Adefovir Dipivoxil—Pancreatitis—Methotrexate—urinary bladder cancer	0.000323	0.0021	CcSEcCtD
Adefovir Dipivoxil—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000318	0.00207	CcSEcCtD
Adefovir Dipivoxil—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000317	0.00206	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000316	0.00205	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—TYMP—urinary bladder cancer	0.000316	0.00252	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000316	0.00252	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000316	0.00252	CbGpPWpGaD
Adefovir Dipivoxil—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000314	0.00204	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000314	0.00251	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000313	0.0025	CbGpPWpGaD
Adefovir Dipivoxil—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000313	0.00203	CcSEcCtD
Adefovir Dipivoxil—Asthenia—Thiotepa—urinary bladder cancer	0.000312	0.00203	CcSEcCtD
Adefovir Dipivoxil—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000311	0.00202	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000311	0.00202	CcSEcCtD
Adefovir Dipivoxil—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000309	0.00201	CcSEcCtD
Adefovir Dipivoxil—Pruritus—Thiotepa—urinary bladder cancer	0.000308	0.002	CcSEcCtD
Adefovir Dipivoxil—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000306	0.00199	CcSEcCtD
Adefovir Dipivoxil—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000305	0.00198	CcSEcCtD
Adefovir Dipivoxil—Skin disorder—Etoposide—urinary bladder cancer	0.000304	0.00197	CcSEcCtD
Adefovir Dipivoxil—Pancreatitis—Epirubicin—urinary bladder cancer	0.000302	0.00196	CcSEcCtD
Adefovir Dipivoxil—Anorexia—Etoposide—urinary bladder cancer	0.000298	0.00194	CcSEcCtD
Adefovir Dipivoxil—Diarrhoea—Thiotepa—urinary bladder cancer	0.000298	0.00193	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—CYP4B1—urinary bladder cancer	0.000298	0.00238	CbGpPWpGaD
Adefovir Dipivoxil—Decreased appetite—Cisplatin—urinary bladder cancer	0.000297	0.00193	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000295	0.00191	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000294	0.00235	CbGpPWpGaD
Adefovir Dipivoxil—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000291	0.00189	CcSEcCtD
Adefovir Dipivoxil—ABCC5—NRF2 pathway—GSTP1—urinary bladder cancer	0.00029	0.00232	CbGpPWpGaD
Adefovir Dipivoxil—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000289	0.00188	CcSEcCtD
Adefovir Dipivoxil—NME1—Metabolism—GSTZ1—urinary bladder cancer	0.000289	0.00231	CbGpPWpGaD
Adefovir Dipivoxil—Renal failure—Methotrexate—urinary bladder cancer	0.000289	0.00188	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—NAT2—urinary bladder cancer	0.000286	0.00228	CbGpPWpGaD
Adefovir Dipivoxil—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000285	0.00185	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—SLC19A1—urinary bladder cancer	0.000281	0.00225	CbGpPWpGaD
Adefovir Dipivoxil—Haematuria—Methotrexate—urinary bladder cancer	0.00028	0.00182	CcSEcCtD
Adefovir Dipivoxil—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00028	0.00182	CcSEcCtD
Adefovir Dipivoxil—Weight decreased—Epirubicin—urinary bladder cancer	0.000279	0.00181	CcSEcCtD
Adefovir Dipivoxil—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000278	0.0018	CcSEcCtD
Adefovir Dipivoxil—Vomiting—Thiotepa—urinary bladder cancer	0.000277	0.0018	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000274	0.00219	CbGpPWpGaD
Adefovir Dipivoxil—Rash—Thiotepa—urinary bladder cancer	0.000274	0.00178	CcSEcCtD
Adefovir Dipivoxil—Dermatitis—Thiotepa—urinary bladder cancer	0.000274	0.00178	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—PRSS3—urinary bladder cancer	0.000274	0.00219	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—GSTO2—urinary bladder cancer	0.000274	0.00219	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—NAT1—urinary bladder cancer	0.000274	0.00219	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Carbohydrate metabolism—ENO2—urinary bladder cancer	0.000273	0.00218	CbGpPWpGaD
Adefovir Dipivoxil—Headache—Thiotepa—urinary bladder cancer	0.000273	0.00177	CcSEcCtD
Adefovir Dipivoxil—Decreased appetite—Etoposide—urinary bladder cancer	0.000272	0.00177	CcSEcCtD
Adefovir Dipivoxil—NME1—Validated targets of C-MYC transcriptional activation—TP53—urinary bladder cancer	0.000271	0.00217	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000271	0.00217	CbGpPWpGaD
Adefovir Dipivoxil—Renal failure—Epirubicin—urinary bladder cancer	0.00027	0.00175	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00027	0.00175	CcSEcCtD
Adefovir Dipivoxil—Body temperature increased—Cisplatin—urinary bladder cancer	0.00027	0.00175	CcSEcCtD
Adefovir Dipivoxil—Jaundice—Epirubicin—urinary bladder cancer	0.000268	0.00174	CcSEcCtD
Adefovir Dipivoxil—ABCC5—NRF2 pathway—GSTM1—urinary bladder cancer	0.000267	0.00213	CbGpPWpGaD
Adefovir Dipivoxil—Hepatitis—Methotrexate—urinary bladder cancer	0.000264	0.00171	CcSEcCtD
Adefovir Dipivoxil—Asthenia—Gemcitabine—urinary bladder cancer	0.000263	0.00171	CcSEcCtD
Adefovir Dipivoxil—Haematuria—Epirubicin—urinary bladder cancer	0.000262	0.0017	CcSEcCtD
Adefovir Dipivoxil—Pharyngitis—Methotrexate—urinary bladder cancer	0.000262	0.0017	CcSEcCtD
Adefovir Dipivoxil—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00026	0.00169	CcSEcCtD
Adefovir Dipivoxil—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00026	0.00169	CcSEcCtD
Adefovir Dipivoxil—Pruritus—Gemcitabine—urinary bladder cancer	0.000259	0.00168	CcSEcCtD
Adefovir Dipivoxil—Nausea—Thiotepa—urinary bladder cancer	0.000259	0.00168	CcSEcCtD
Adefovir Dipivoxil—Urethral disorder—Methotrexate—urinary bladder cancer	0.000258	0.00168	CcSEcCtD
Adefovir Dipivoxil—Weight decreased—Doxorubicin—urinary bladder cancer	0.000258	0.00168	CcSEcCtD
Adefovir Dipivoxil—Sinusitis—Epirubicin—urinary bladder cancer	0.000258	0.00167	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000256	0.00166	CcSEcCtD
Adefovir Dipivoxil—Pruritus—Fluorouracil—urinary bladder cancer	0.000255	0.00165	CcSEcCtD
Adefovir Dipivoxil—SLC22A3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000253	0.00202	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—UGT2B7—urinary bladder cancer	0.000251	0.002	CbGpPWpGaD
Adefovir Dipivoxil—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00025	0.00163	CcSEcCtD
Adefovir Dipivoxil—Renal failure—Doxorubicin—urinary bladder cancer	0.00025	0.00162	CcSEcCtD
Adefovir Dipivoxil—Jaundice—Doxorubicin—urinary bladder cancer	0.000248	0.00161	CcSEcCtD
Adefovir Dipivoxil—Body temperature increased—Etoposide—urinary bladder cancer	0.000247	0.00161	CcSEcCtD
Adefovir Dipivoxil—Abdominal pain—Etoposide—urinary bladder cancer	0.000247	0.00161	CcSEcCtD
Adefovir Dipivoxil—Hepatitis—Epirubicin—urinary bladder cancer	0.000247	0.0016	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—RRM2—urinary bladder cancer	0.000247	0.00197	CbGpPWpGaD
Adefovir Dipivoxil—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000246	0.0016	CcSEcCtD
Adefovir Dipivoxil—Asthenia—Cisplatin—urinary bladder cancer	0.000245	0.00159	CcSEcCtD
Adefovir Dipivoxil—Pharyngitis—Epirubicin—urinary bladder cancer	0.000245	0.00159	CcSEcCtD
Adefovir Dipivoxil—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000244	0.00158	CcSEcCtD
Adefovir Dipivoxil—Haematuria—Doxorubicin—urinary bladder cancer	0.000242	0.00157	CcSEcCtD
Adefovir Dipivoxil—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000242	0.00157	CcSEcCtD
Adefovir Dipivoxil—Urethral disorder—Epirubicin—urinary bladder cancer	0.000242	0.00157	CcSEcCtD
Adefovir Dipivoxil—ABCC4—NRF2 pathway—NQO1—urinary bladder cancer	0.000241	0.00193	CbGpPWpGaD
Adefovir Dipivoxil—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00024	0.00156	CcSEcCtD
Adefovir Dipivoxil—Sinusitis—Doxorubicin—urinary bladder cancer	0.000239	0.00155	CcSEcCtD
Adefovir Dipivoxil—Diarrhoea—Cisplatin—urinary bladder cancer	0.000233	0.00152	CcSEcCtD
Adefovir Dipivoxil—Vomiting—Gemcitabine—urinary bladder cancer	0.000233	0.00151	CcSEcCtD
Adefovir Dipivoxil—Rash—Gemcitabine—urinary bladder cancer	0.000231	0.0015	CcSEcCtD
Adefovir Dipivoxil—Dermatitis—Gemcitabine—urinary bladder cancer	0.000231	0.0015	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.00023	0.00184	CbGpPWpGaD
Adefovir Dipivoxil—Malnutrition—Methotrexate—urinary bladder cancer	0.000229	0.00149	CcSEcCtD
Adefovir Dipivoxil—Headache—Gemcitabine—urinary bladder cancer	0.000229	0.00149	CcSEcCtD
Adefovir Dipivoxil—Vomiting—Fluorouracil—urinary bladder cancer	0.000229	0.00149	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—HPGDS—urinary bladder cancer	0.000228	0.00183	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—ENO2—urinary bladder cancer	0.000228	0.00183	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000228	0.00182	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A8—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000228	0.00182	CbGpPWpGaD
Adefovir Dipivoxil—Hepatitis—Doxorubicin—urinary bladder cancer	0.000228	0.00148	CcSEcCtD
Adefovir Dipivoxil—Rash—Fluorouracil—urinary bladder cancer	0.000227	0.00147	CcSEcCtD
Adefovir Dipivoxil—Dermatitis—Fluorouracil—urinary bladder cancer	0.000227	0.00147	CcSEcCtD
Adefovir Dipivoxil—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000227	0.00147	CcSEcCtD
Adefovir Dipivoxil—NME1—Metabolism—CYP4B1—urinary bladder cancer	0.000226	0.0018	CbGpPWpGaD
Adefovir Dipivoxil—Headache—Fluorouracil—urinary bladder cancer	0.000226	0.00147	CcSEcCtD
Adefovir Dipivoxil—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000225	0.00146	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000225	0.0018	CbGpPWpGaD
Adefovir Dipivoxil—Asthenia—Etoposide—urinary bladder cancer	0.000224	0.00146	CcSEcCtD
Adefovir Dipivoxil—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000224	0.00146	CcSEcCtD
Adefovir Dipivoxil—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000224	0.00145	CcSEcCtD
Adefovir Dipivoxil—Back pain—Methotrexate—urinary bladder cancer	0.000222	0.00144	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—GSTT1—urinary bladder cancer	0.000222	0.00177	CbGpPWpGaD
Adefovir Dipivoxil—Pruritus—Etoposide—urinary bladder cancer	0.000221	0.00144	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—TYMP—urinary bladder cancer	0.000219	0.00175	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000219	0.00175	CbGpPWpGaD
Adefovir Dipivoxil—Nausea—Gemcitabine—urinary bladder cancer	0.000217	0.00141	CcSEcCtD
Adefovir Dipivoxil—Vomiting—Cisplatin—urinary bladder cancer	0.000217	0.00141	CcSEcCtD
Adefovir Dipivoxil—Rash—Cisplatin—urinary bladder cancer	0.000215	0.0014	CcSEcCtD
Adefovir Dipivoxil—Dermatitis—Cisplatin—urinary bladder cancer	0.000215	0.0014	CcSEcCtD
Adefovir Dipivoxil—Malnutrition—Epirubicin—urinary bladder cancer	0.000215	0.0014	CcSEcCtD
Adefovir Dipivoxil—Diarrhoea—Etoposide—urinary bladder cancer	0.000214	0.00139	CcSEcCtD
Adefovir Dipivoxil—Nausea—Fluorouracil—urinary bladder cancer	0.000214	0.00139	CcSEcCtD
Adefovir Dipivoxil—NME1—Metabolism—SLC19A1—urinary bladder cancer	0.000213	0.0017	CbGpPWpGaD
Adefovir Dipivoxil—Anaemia—Methotrexate—urinary bladder cancer	0.000212	0.00138	CcSEcCtD
Adefovir Dipivoxil—Flatulence—Epirubicin—urinary bladder cancer	0.000212	0.00137	CcSEcCtD
Adefovir Dipivoxil—Back pain—Epirubicin—urinary bladder cancer	0.000208	0.00135	CcSEcCtD
Adefovir Dipivoxil—NME1—Metabolism—PRSS3—urinary bladder cancer	0.000208	0.00166	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000204	0.00163	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Platelet degranulation—IGF1—urinary bladder cancer	0.000204	0.00163	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.000203	0.00162	CbGpPWpGaD
Adefovir Dipivoxil—Nausea—Cisplatin—urinary bladder cancer	0.000203	0.00132	CcSEcCtD
Adefovir Dipivoxil—ABCC4—NRF2 pathway—GSTP1—urinary bladder cancer	0.000201	0.00161	CbGpPWpGaD
Adefovir Dipivoxil—Cough—Methotrexate—urinary bladder cancer	0.0002	0.0013	CcSEcCtD
Adefovir Dipivoxil—Vomiting—Etoposide—urinary bladder cancer	0.000199	0.00129	CcSEcCtD
Adefovir Dipivoxil—Malnutrition—Doxorubicin—urinary bladder cancer	0.000199	0.00129	CcSEcCtD
Adefovir Dipivoxil—Anaemia—Epirubicin—urinary bladder cancer	0.000198	0.00129	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—NAT2—urinary bladder cancer	0.000198	0.00158	CbGpPWpGaD
Adefovir Dipivoxil—Rash—Etoposide—urinary bladder cancer	0.000197	0.00128	CcSEcCtD
Adefovir Dipivoxil—Dermatitis—Etoposide—urinary bladder cancer	0.000197	0.00128	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	0.000196	0.00157	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	0.000196	0.00157	CbGpPWpGaD
Adefovir Dipivoxil—Headache—Etoposide—urinary bladder cancer	0.000196	0.00127	CcSEcCtD
Adefovir Dipivoxil—Flatulence—Doxorubicin—urinary bladder cancer	0.000196	0.00127	CcSEcCtD
Adefovir Dipivoxil—Chest pain—Methotrexate—urinary bladder cancer	0.000195	0.00127	CcSEcCtD
Adefovir Dipivoxil—Myalgia—Methotrexate—urinary bladder cancer	0.000195	0.00127	CcSEcCtD
Adefovir Dipivoxil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000194	0.00126	CcSEcCtD
Adefovir Dipivoxil—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	0.000194	0.00155	CbGpPWpGaD
Adefovir Dipivoxil—Back pain—Doxorubicin—urinary bladder cancer	0.000192	0.00125	CcSEcCtD
Adefovir Dipivoxil—SLC22A6—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000191	0.00152	CbGpPWpGaD
Adefovir Dipivoxil—Cough—Epirubicin—urinary bladder cancer	0.000187	0.00122	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	0.000187	0.00149	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000186	0.00149	CbGpPWpGaD
Adefovir Dipivoxil—Nausea—Etoposide—urinary bladder cancer	0.000186	0.00121	CcSEcCtD
Adefovir Dipivoxil—ABCC4—NRF2 pathway—GSTM1—urinary bladder cancer	0.000185	0.00148	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—NQO1—urinary bladder cancer	0.000184	0.00147	CbGpPWpGaD
Adefovir Dipivoxil—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000184	0.00119	CcSEcCtD
Adefovir Dipivoxil—Anaemia—Doxorubicin—urinary bladder cancer	0.000184	0.00119	CcSEcCtD
Adefovir Dipivoxil—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000183	0.00119	CcSEcCtD
Adefovir Dipivoxil—SLC22A3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000183	0.00146	CbGpPWpGaD
Adefovir Dipivoxil—Myalgia—Epirubicin—urinary bladder cancer	0.000183	0.00119	CcSEcCtD
Adefovir Dipivoxil—Chest pain—Epirubicin—urinary bladder cancer	0.000183	0.00119	CcSEcCtD
Adefovir Dipivoxil—Skin disorder—Methotrexate—urinary bladder cancer	0.000182	0.00118	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	0.000182	0.00145	CbGpPWpGaD
Adefovir Dipivoxil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000182	0.00118	CcSEcCtD
Adefovir Dipivoxil—Anorexia—Methotrexate—urinary bladder cancer	0.000178	0.00116	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Disease—GSTO2—urinary bladder cancer	0.000177	0.00141	CbGpPWpGaD
Adefovir Dipivoxil—Cough—Doxorubicin—urinary bladder cancer	0.000173	0.00113	CcSEcCtD
Adefovir Dipivoxil—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000172	0.00112	CcSEcCtD
Adefovir Dipivoxil—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000172	0.00111	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—RRM2—urinary bladder cancer	0.000171	0.00137	CbGpPWpGaD
Adefovir Dipivoxil—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000171	0.00111	CcSEcCtD
Adefovir Dipivoxil—Skin disorder—Epirubicin—urinary bladder cancer	0.00017	0.00111	CcSEcCtD
Adefovir Dipivoxil—Chest pain—Doxorubicin—urinary bladder cancer	0.000169	0.0011	CcSEcCtD
Adefovir Dipivoxil—Myalgia—Doxorubicin—urinary bladder cancer	0.000169	0.0011	CcSEcCtD
Adefovir Dipivoxil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000168	0.00109	CcSEcCtD
Adefovir Dipivoxil—Anorexia—Epirubicin—urinary bladder cancer	0.000167	0.00109	CcSEcCtD
Adefovir Dipivoxil—NME1—Metabolism—TYMP—urinary bladder cancer	0.000166	0.00133	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A8—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000165	0.00132	CbGpPWpGaD
Adefovir Dipivoxil—Dyspepsia—Methotrexate—urinary bladder cancer	0.000165	0.00107	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.000163	0.0013	CbGpPWpGaD
Adefovir Dipivoxil—Decreased appetite—Methotrexate—urinary bladder cancer	0.000163	0.00106	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000162	0.00105	CcSEcCtD
Adefovir Dipivoxil—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00016	0.00104	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.000159	0.00127	CbGpPWpGaD
Adefovir Dipivoxil—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000159	0.00103	CcSEcCtD
Adefovir Dipivoxil—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000159	0.00103	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—HPGDS—urinary bladder cancer	0.000158	0.00126	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—ENO2—urinary bladder cancer	0.000158	0.00126	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000158	0.00126	CbGpPWpGaD
Adefovir Dipivoxil—Skin disorder—Doxorubicin—urinary bladder cancer	0.000157	0.00102	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Metabolism—GSTZ1—urinary bladder cancer	0.000156	0.00125	CbGpPWpGaD
Adefovir Dipivoxil—Anorexia—Doxorubicin—urinary bladder cancer	0.000155	0.001	CcSEcCtD
Adefovir Dipivoxil—Dyspepsia—Epirubicin—urinary bladder cancer	0.000154	0.001	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—GSTT1—urinary bladder cancer	0.000154	0.00123	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—GSTP1—urinary bladder cancer	0.000154	0.00123	CbGpPWpGaD
Adefovir Dipivoxil—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000153	0.000995	CcSEcCtD
Adefovir Dipivoxil—Decreased appetite—Epirubicin—urinary bladder cancer	0.000152	0.00099	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.000152	0.00121	CbGpPWpGaD
Adefovir Dipivoxil—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000151	0.000983	CcSEcCtD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.00015	0.0012	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—NAT2—urinary bladder cancer	0.00015	0.0012	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000149	0.00119	CbGpPWpGaD
Adefovir Dipivoxil—Abdominal pain—Methotrexate—urinary bladder cancer	0.000148	0.000962	CcSEcCtD
Adefovir Dipivoxil—Body temperature increased—Methotrexate—urinary bladder cancer	0.000148	0.000962	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Metabolism—NAT1—urinary bladder cancer	0.000148	0.00118	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—GSTO2—urinary bladder cancer	0.000148	0.00118	CbGpPWpGaD
Adefovir Dipivoxil—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000148	0.00096	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000143	0.000931	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—TYMS—urinary bladder cancer	0.000143	0.00114	CbGpPWpGaD
Adefovir Dipivoxil—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000143	0.000927	CcSEcCtD
Adefovir Dipivoxil—AK2—Metabolism—GSTM1—urinary bladder cancer	0.000141	0.00113	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—NCOR1—urinary bladder cancer	0.000141	0.00113	CbGpPWpGaD
Adefovir Dipivoxil—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000141	0.000916	CcSEcCtD
Adefovir Dipivoxil—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00014	0.00091	CcSEcCtD
Adefovir Dipivoxil—Abdominal pain—Epirubicin—urinary bladder cancer	0.000139	0.0009	CcSEcCtD
Adefovir Dipivoxil—Body temperature increased—Epirubicin—urinary bladder cancer	0.000139	0.0009	CcSEcCtD
Adefovir Dipivoxil—SLC22A6—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000138	0.0011	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—SLC19A1—urinary bladder cancer	0.000137	0.0011	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—UGT2B7—urinary bladder cancer	0.000135	0.00108	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—GPX1—urinary bladder cancer	0.000135	0.00108	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A8—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000135	0.00108	CbGpPWpGaD
Adefovir Dipivoxil—Asthenia—Methotrexate—urinary bladder cancer	0.000134	0.000873	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Disease—PRSS3—urinary bladder cancer	0.000134	0.00107	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.000134	0.00107	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—ERCC2—urinary bladder cancer	0.000133	0.00106	CbGpPWpGaD
Adefovir Dipivoxil—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000133	0.000861	CcSEcCtD
Adefovir Dipivoxil—Pruritus—Methotrexate—urinary bladder cancer	0.000132	0.000861	CcSEcCtD
Adefovir Dipivoxil—NME1—Metabolism—RRM2—urinary bladder cancer	0.00013	0.00104	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000129	0.00103	CbGpPWpGaD
Adefovir Dipivoxil—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000128	0.000833	CcSEcCtD
Adefovir Dipivoxil—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000128	0.000833	CcSEcCtD
Adefovir Dipivoxil—Diarrhoea—Methotrexate—urinary bladder cancer	0.000128	0.000832	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Disease—HDAC4—urinary bladder cancer	0.000128	0.00102	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—NQO1—urinary bladder cancer	0.000128	0.00102	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000126	0.001	CbGpPWpGaD
Adefovir Dipivoxil—Asthenia—Epirubicin—urinary bladder cancer	0.000126	0.000817	CcSEcCtD
Adefovir Dipivoxil—SLC22A3—Metabolism—GSTZ1—urinary bladder cancer	0.000125	0.001	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—MTHFR—urinary bladder cancer	0.000125	0.000996	CbGpPWpGaD
Adefovir Dipivoxil—Pruritus—Epirubicin—urinary bladder cancer	0.000124	0.000806	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Metabolism—CYP4B1—urinary bladder cancer	0.000122	0.000973	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—HPGDS—urinary bladder cancer	0.00012	0.000959	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—ENO2—urinary bladder cancer	0.00012	0.000959	CbGpPWpGaD
Adefovir Dipivoxil—Diarrhoea—Epirubicin—urinary bladder cancer	0.00012	0.000779	CcSEcCtD
Adefovir Dipivoxil—Vomiting—Methotrexate—urinary bladder cancer	0.000119	0.000774	CcSEcCtD
Adefovir Dipivoxil—SLC22A3—Metabolism—NAT1—urinary bladder cancer	0.000119	0.000948	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—GSTO2—urinary bladder cancer	0.000119	0.000948	CbGpPWpGaD
Adefovir Dipivoxil—Rash—Methotrexate—urinary bladder cancer	0.000118	0.000767	CcSEcCtD
Adefovir Dipivoxil—Dermatitis—Methotrexate—urinary bladder cancer	0.000118	0.000766	CcSEcCtD
Adefovir Dipivoxil—Headache—Methotrexate—urinary bladder cancer	0.000117	0.000762	CcSEcCtD
Adefovir Dipivoxil—NME1—Metabolism—GSTT1—urinary bladder cancer	0.000116	0.00093	CbGpPWpGaD
Adefovir Dipivoxil—Asthenia—Doxorubicin—urinary bladder cancer	0.000116	0.000756	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Metabolism—SLC19A1—urinary bladder cancer	0.000115	0.000919	CbGpPWpGaD
Adefovir Dipivoxil—Pruritus—Doxorubicin—urinary bladder cancer	0.000115	0.000745	CcSEcCtD
Adefovir Dipivoxil—SLC22A6—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000112	0.000897	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—PRSS3—urinary bladder cancer	0.000112	0.000896	CbGpPWpGaD
Adefovir Dipivoxil—Vomiting—Epirubicin—urinary bladder cancer	0.000111	0.000724	CcSEcCtD
Adefovir Dipivoxil—Nausea—Methotrexate—urinary bladder cancer	0.000111	0.000723	CcSEcCtD
Adefovir Dipivoxil—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000111	0.000721	CcSEcCtD
Adefovir Dipivoxil—Rash—Epirubicin—urinary bladder cancer	0.00011	0.000718	CcSEcCtD
Adefovir Dipivoxil—Dermatitis—Epirubicin—urinary bladder cancer	0.00011	0.000717	CcSEcCtD
Adefovir Dipivoxil—Headache—Epirubicin—urinary bladder cancer	0.00011	0.000713	CcSEcCtD
Adefovir Dipivoxil—SLC22A3—Metabolism—UGT2B7—urinary bladder cancer	0.000109	0.000867	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—GSTP1—urinary bladder cancer	0.000106	0.00085	CbGpPWpGaD
Adefovir Dipivoxil—Nausea—Epirubicin—urinary bladder cancer	0.000104	0.000676	CcSEcCtD
Adefovir Dipivoxil—Vomiting—Doxorubicin—urinary bladder cancer	0.000103	0.00067	CcSEcCtD
Adefovir Dipivoxil—Rash—Doxorubicin—urinary bladder cancer	0.000102	0.000664	CcSEcCtD
Adefovir Dipivoxil—Dermatitis—Doxorubicin—urinary bladder cancer	0.000102	0.000664	CcSEcCtD
Adefovir Dipivoxil—Headache—Doxorubicin—urinary bladder cancer	0.000102	0.00066	CcSEcCtD
Adefovir Dipivoxil—ABCC5—Disease—LIG1—urinary bladder cancer	0.000101	0.000811	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—PPARG—urinary bladder cancer	0.000101	0.000808	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000101	0.000806	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—TYMS—urinary bladder cancer	9.9e-05	0.000791	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—NCOR1—urinary bladder cancer	9.78e-05	0.000782	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—GSTM1—urinary bladder cancer	9.78e-05	0.000782	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—CYP4B1—urinary bladder cancer	9.77e-05	0.000781	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—CREBBP—urinary bladder cancer	9.72e-05	0.000776	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—NQO1—urinary bladder cancer	9.67e-05	0.000773	CbGpPWpGaD
Adefovir Dipivoxil—Nausea—Doxorubicin—urinary bladder cancer	9.63e-05	0.000626	CcSEcCtD
Adefovir Dipivoxil—NME2—Metabolism—GPX1—urinary bladder cancer	9.37e-05	0.000748	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—SLC19A1—urinary bladder cancer	9.23e-05	0.000737	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—ERCC2—urinary bladder cancer	9.2e-05	0.000735	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A8—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.09e-05	0.000726	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	9.03e-05	0.000721	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—PRSS3—urinary bladder cancer	8.99e-05	0.000718	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—TYMP—urinary bladder cancer	8.96e-05	0.000716	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.72e-05	0.000696	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—MTHFR—urinary bladder cancer	8.64e-05	0.000691	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	8.27e-05	0.000661	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—NAT2—urinary bladder cancer	8.11e-05	0.000648	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—GSTP1—urinary bladder cancer	8.07e-05	0.000645	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—IFNA2—urinary bladder cancer	8.05e-05	0.000643	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—PTGS2—urinary bladder cancer	7.96e-05	0.000636	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Ectoderm Differentiation—MYC—urinary bladder cancer	7.91e-05	0.000632	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—ENO2—urinary bladder cancer	7.74e-05	0.000618	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.59e-05	0.000606	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—TYMS—urinary bladder cancer	7.5e-05	0.000599	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—GSTM1—urinary bladder cancer	7.41e-05	0.000592	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—NCOR1—urinary bladder cancer	7.41e-05	0.000592	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—RBX1—urinary bladder cancer	7.33e-05	0.000586	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—TYMP—urinary bladder cancer	7.19e-05	0.000574	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—GPX1—urinary bladder cancer	7.1e-05	0.000567	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—PPARG—urinary bladder cancer	7.01e-05	0.00056	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—RRM2—urinary bladder cancer	7e-05	0.000559	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—ERCC2—urinary bladder cancer	6.97e-05	0.000557	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—PTEN—urinary bladder cancer	6.94e-05	0.000554	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	6.94e-05	0.000554	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—CREBBP—urinary bladder cancer	6.73e-05	0.000538	CbGpPWpGaD
Adefovir Dipivoxil—AK2—Metabolism—EP300—urinary bladder cancer	6.62e-05	0.000529	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—JAG1—urinary bladder cancer	6.56e-05	0.000525	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—MTHFR—urinary bladder cancer	6.55e-05	0.000523	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—NAT2—urinary bladder cancer	6.5e-05	0.000519	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—ENO2—urinary bladder cancer	6.48e-05	0.000518	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—HPGDS—urinary bladder cancer	6.48e-05	0.000518	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—GSTT1—urinary bladder cancer	6.28e-05	0.000502	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	6.05e-05	0.000484	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.88e-05	0.00047	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—PLAU—urinary bladder cancer	5.71e-05	0.000456	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—RRM2—urinary bladder cancer	5.61e-05	0.000448	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—PTGS2—urinary bladder cancer	5.51e-05	0.000441	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—PPARG—urinary bladder cancer	5.31e-05	0.000424	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—NQO1—urinary bladder cancer	5.22e-05	0.000417	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—ENO2—urinary bladder cancer	5.2e-05	0.000415	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—HPGDS—urinary bladder cancer	5.2e-05	0.000415	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—CREBBP—urinary bladder cancer	5.1e-05	0.000408	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—GSTT1—urinary bladder cancer	5.04e-05	0.000403	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—PTEN—urinary bladder cancer	4.81e-05	0.000384	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—NCOR1—urinary bladder cancer	4.78e-05	0.000382	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.72e-05	0.000377	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—CREBBP—urinary bladder cancer	4.71e-05	0.000376	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—IGF1—urinary bladder cancer	4.65e-05	0.000372	CbGpPWpGaD
Adefovir Dipivoxil—NME2—Metabolism—EP300—urinary bladder cancer	4.59e-05	0.000366	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—ERCC2—urinary bladder cancer	4.49e-05	0.000359	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—GSTP1—urinary bladder cancer	4.36e-05	0.000348	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—RHOA—urinary bladder cancer	4.26e-05	0.000341	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.25e-05	0.00034	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—MTHFR—urinary bladder cancer	4.22e-05	0.000338	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—TERT—urinary bladder cancer	4.21e-05	0.000337	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—NQO1—urinary bladder cancer	4.19e-05	0.000335	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—PTGS2—urinary bladder cancer	4.18e-05	0.000334	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.08e-05	0.000326	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—TYMS—urinary bladder cancer	4.05e-05	0.000324	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—GSTM1—urinary bladder cancer	4e-05	0.00032	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—NCOR1—urinary bladder cancer	4e-05	0.00032	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—FGFR3—urinary bladder cancer	3.87e-05	0.000309	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—GPX1—urinary bladder cancer	3.83e-05	0.000306	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—ERCC2—urinary bladder cancer	3.76e-05	0.000301	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—PTEN—urinary bladder cancer	3.64e-05	0.000291	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—IL2—urinary bladder cancer	3.58e-05	0.000286	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.55e-05	0.000284	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—MTHFR—urinary bladder cancer	3.54e-05	0.000283	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—GSTP1—urinary bladder cancer	3.49e-05	0.000279	CbGpPWpGaD
Adefovir Dipivoxil—NME1—Metabolism—EP300—urinary bladder cancer	3.48e-05	0.000278	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—CREBBP—urinary bladder cancer	3.29e-05	0.000263	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—TYMS—urinary bladder cancer	3.25e-05	0.00026	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—GSTM1—urinary bladder cancer	3.21e-05	0.000257	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—NCOR1—urinary bladder cancer	3.21e-05	0.000257	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—EP300—urinary bladder cancer	3.21e-05	0.000256	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—SRC—urinary bladder cancer	3.12e-05	0.000249	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—GPX1—urinary bladder cancer	3.07e-05	0.000246	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—ERCC2—urinary bladder cancer	3.02e-05	0.000241	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—RHOA—urinary bladder cancer	2.98e-05	0.000238	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—PPARG—urinary bladder cancer	2.87e-05	0.000229	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—MTHFR—urinary bladder cancer	2.84e-05	0.000227	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—CREBBP—urinary bladder cancer	2.76e-05	0.00022	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—ERBB2—urinary bladder cancer	2.76e-05	0.00022	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—PTGS2—urinary bladder cancer	2.69e-05	0.000215	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—KRAS—urinary bladder cancer	2.58e-05	0.000206	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—CDKN1A—urinary bladder cancer	2.36e-05	0.000188	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—PTEN—urinary bladder cancer	2.35e-05	0.000188	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—PPARG—urinary bladder cancer	2.3e-05	0.000184	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—TP53—urinary bladder cancer	2.3e-05	0.000183	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—PTGS2—urinary bladder cancer	2.26e-05	0.00018	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—EP300—urinary bladder cancer	2.24e-05	0.000179	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—CREBBP—urinary bladder cancer	2.21e-05	0.000177	CbGpPWpGaD
Adefovir Dipivoxil—ABCC4—Hemostasis—HRAS—urinary bladder cancer	2.2e-05	0.000175	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—SRC—urinary bladder cancer	2.18e-05	0.000174	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—PTEN—urinary bladder cancer	1.97e-05	0.000157	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—MYC—urinary bladder cancer	1.95e-05	0.000156	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—EGFR—urinary bladder cancer	1.91e-05	0.000153	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Metabolism—EP300—urinary bladder cancer	1.88e-05	0.00015	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—PTGS2—urinary bladder cancer	1.81e-05	0.000145	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—KRAS—urinary bladder cancer	1.8e-05	0.000144	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—PTEN—urinary bladder cancer	1.58e-05	0.000126	CbGpPWpGaD
Adefovir Dipivoxil—ABCC5—Disease—HRAS—urinary bladder cancer	1.53e-05	0.000123	CbGpPWpGaD
Adefovir Dipivoxil—SLC22A3—Metabolism—EP300—urinary bladder cancer	1.51e-05	0.00012	CbGpPWpGaD
